WEST POINT, N.Y. – In a significant advancement for military medical logistics, Keller Army Community Hospital (KACH) has secured critical flight approvals, marking a new phase for its ambitious drone ...

The latest headlines from our reporters across the US sent straight to your inbox each weekday Your briefing on the latest headlines from across the US Two people became “deathly ill” after allegedly ...

BOSTON, MA, UNITED STATES, January 14, 2026 /EINPresswire.com/ — Creatio, a global vendor of an agentic CRM and workflow platform with no-code and AI at its core ...

Uinta - Test Phase (Lab Sequence 004): As the name denotes, this is the fourth iteration of Uinta’s newest line of rotating IPAs, and features Dolicita, Alora and HBC-630 hops. From the first crack of ...

As governments, technology leaders, and financial institutions accelerate investment into quantum computing, a growing gap has emerged between public perception and technical reality. To address this ...

Welcome to Edition 8.26 of the Rocket Report! The past week has been one of advancements and setbacks in the rocket business. NASA rolled the massive rocket for the Artemis II mission to its launch ...

Global pharmaceutical output surged in 2025 due to preemptive production ahead of U.S. tariff actions, with a 9.1% increase in manufacturing output. The pharmaceutical sector benefits from structural ...

Retail media has been slow to evolve in the grocery industry, but signs of acceleration have emerged in recent months. Albertsons Media Collective announced in early January the launch of an in-store ...

Add Yahoo as a preferred source to see more of our stories on Google. Moon Knight to play a major role in rumored Midnight Sons movie While never officially confirmed by Marvel Studios, the Midnight ...

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA. The British drugmaker had been ...

(RTTNews) - Corbus Pharmaceuticals Holdings Inc. (CRBP) will present results from its Phase 1a study of CRB-913, an oral CB1 inverse agonist, for the treatment of obesity during a webcast scheduled ...